Thus, when a preservation of the insulinotropic effects of GLP-1 in obesity was established (128), excitement surrounding the possible therapeutic application of this newly discovered incretin hormone began to grow. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.